111In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
111In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
复制标题
DOI：
10.2310/7290.2014.00011
复制
发表时间：
2014-07-01
影响因子：
2.8
通讯作者：
Lub-de Hooge, Marjolijn N.
中科院分区：
文献类型：
--
作者：
Gaykema, Sietske B. M.;de Jong, Johan R.;Lub-de Hooge, Marjolijn N.
人表皮生长因子受体(HER)2放射性标记曲妥珠单抗显像可能支持HER2靶向治疗。然而，人们经常质疑在曲妥珠单抗治疗期间是否也可以进行HER2成像，因为受体可能是饱和的。我们研究了曲妥珠单抗治疗对In-111-曲妥珠单抗摄取的影响。曲妥珠单抗每周一次，紫杉醇每三周一次。分别于第1周期第1天和第4周期第15天注射In-111-曲妥珠单抗，于注射后不同时间点进行全身核素扫描。通过滞留时间计算首次扫描和重复扫描序列之间的肿瘤摄取和器官分布。12例患者的25个肿瘤病灶在两个系列的核素扫描中均可显示。肿瘤摄取减少(19.6%；p=0.03)。除心血池外，正常器官的停留时间相似(+16.3%；p=.014)。曲妥珠单抗治疗使肿瘤对曲妥珠单抗的摄取减少约20%。曲妥珠单抗治疗期间HER2显像是可行的。
Human epidermal growth factor receptor (HER)2 imaging with radiolabeled trastuzumab might support HER2-targeted therapy. It is, however, frequently questioned whether HER2 imaging is also possible during trastuzumab treatment as the receptor might be saturated. We studied the effect of trastuzumab treatment on In-111-trastuzumab uptake. Patients received trastuzumab weekly and paclitaxel once every 3weeks. In-111-trastuzumab was injected on day 1 of cycle 1 and day 15 of cycle 4. Whole-body planar scintigraphy was acquired at different time points postinjection. Tumor uptake and organ distribution between the first and repeated scan series were calculated via residence times. Twenty-five tumor lesions in 12 patients were visualized on both scintigraphy series. Tumor uptake decreased ( 19.6%; p = .03). The residence times of normal organs remained similar except for the cardiac blood pool (+ 16.3%; p = .014). Trastuzumab treatment decreases tumor In-111-trastuzumab uptake around 20%. HER2 imaging is feasible during trastuzumab treatment.